Trends in Neoadjuvant Pembrolizumab Use in Triple-Negative Breast Cancer
This study revealed high rates of pembrolizumab utilization within a year of approval for its use in the treatment of TNBC. There were no significant differences in their use according to race and ethnicity, but patients who lived in areas of higher socioeconomic deprivation had lower rates of use.
Authors
- Ellen Li (ORCID: https://orcid.org/0000-0002-1141-0406)
- Thomas A. Buchholz (ORCID: https://orcid.org/0000-0002-7859-5572)
- Samantha R. Spierling Bagsic (ORCID: https://orcid.org/0000-0003-1274-3736)
- A. Aguayo
- Cammie Nguyen
- S. Ali
- N. Liloia
- Rebecca F. Belasco
- David Lindsay
Institutions
- Scripps Health (US)
- Bucknell University (US)
- Cornell University (US)
- Scripps Clinic Medical Group (US)
- Oncoceutics (United States) (US)
- Scripps (United States) (US)
- Scripps MD Anderson Cancer Center (US)
- Charles R. Drew University of Medicine and Science (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1097/coc.0000000000001305
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00